<DOC>
	<DOCNO>NCT02190305</DOCNO>
	<brief_summary>The purpose study determine efficacy two rapid diagnostic test plasma , venipuncture whole blood , fingerstick whole blood . The clinical performance Multiplo HBc/HIV/HCV determine compare result patient infected status HIV-1/2 ( human immunodeficiency viruses 1 2 ) , HBV ( hepatitis B virus ) HCV ( hepatitis C virus ) . The clinical performance Reveal HBsAg determine compare result patient infected status HBV . Subject participation study consist single one-hour visit , time blood sample draw test investigational device approve comparator assay . The test result , outcome study , obtain , time visit .</brief_summary>
	<brief_title>Rapid Diagnostics HIV Hepatitis</brief_title>
	<detailed_description>The objective study determine performance characteristic two rapid diagnostic test . Approximately 3000-4500 subject total enrol study four different study population . In Population 1 , `` risk '' group 2000-3000 subject , roughly 2/3 individual risk infection HIV hepatitis B C , sign symptom hepatitis . Approximately 500 individual expect known HIV-positive individual . The remain three study population comprise individual know infection HIV ( Population 1A , ~500 individual ) , HBV ( Population 1B , ~500 individual ) , HCV ( Population 1C , ~500 individual ) . Both Multiplo HBc/HIV/HCV Reveal HBsAg use test finger stick whole blood , venous whole blood plasma sample subject Population 1 . Plasma sample ( repository fresh ) use fulfill requirement Populations 1A , 1B , 1C . For enrolled subject , plasma sample test follow FDA-approved assay : EIA anti-HIV-1/2 , anti-HCV , anti-HBc total , anti-HBc IgM , anti-HBs , HBsAg . The efficacy Multiplo determine compare result patient infected status HIV-1/2 , HBV HCV . The efficacy Reveal determine compare result patient infected status HBV . The primary analysis involve comparison Multiplo HBc/HIV/HCV Reveal HBsAg result test marker ( anti-HIV-1/2 , anti-HCV , anti-HBc , HBsAg ) , sample matrix ( finger stick whole blood , venous whole blood plasma ) patient infect status determine separate algorithm HIV , HBV , HCV . The percent positive percent negative agreement determine relative patient infect status marker sample type , correspond two-sided 95 % confidence interval .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>All subject : 13 year age old able sign consent form ( parent/guardian sign consent plus subject sign assent age 1318 ) willing complete risk assessment questionnaire , willing provide blood sample : finger stick sample ( 2 drop ) , 1 serum separator tube , 2 anticoagulant ( K2 EDTA ) tube . Population 1 Diagnostic Trial `` At Risk '' Group ( n = 20003000 ) Subjects must meet one follow inclusion criterion enrol Population 1 : Have least one risk factor infection hepatitis B C , Have least one risk factor infection HIV , Present sign symptom hepatitis , Be know HIVpositive individual ( previous positive HIV test result , may comprise 500 individual ) Population 1A Additional know HIVpositive individual ( n = ~500 ) Subjects must : • know HIVpositive individual ( previous positive HIV test result ) . Population 1B Additional know HBVpositive individual ( n = ~500 ) Subjects must : • know current past HBV infection , evidence HBV serology result . Population 1C Additional know HCVpositive individual ( n = ~500 ) Subjects must : • know infected HCV , evidence previous positive HCV test result . Subjects meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>